Literature DB >> 2380817

Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections.

C G Pribble1, P G Black, J A Bosso, R B Turner.   

Abstract

The purpose of this study was to determine whether acute pulmonary exacerbations of cystic fibrosis associated with nonbacterial infections are clinically distinguishable from other exacerbations. Eighty exacerbations in 54 patients were studied. Exacerbations associated with influenza (n = 8) were compared with those associated with other nonbacterial infections (n = 15) and those in which no nonbacterial infection was detected (n = 57). Patients with influenza had lower Shwachman scores and were more likely to be seropositive for C-reactive protein than patients in the other two groups. Patients with influenza had a mean decrease in forced expiratory volume per second of 26%, compared with test results obtained before the exacerbation. In contrast, the mean decrease in forced expiratory volume per second was 6% for other nonbacterial infections and 12% for the group without nonbacterial infection (p less than 0.05 for both comparisons). The forced expiratory flow in first 25% of vital capacity decreased 44% in the influenza group compared with 13% and 17% in the other two groups, respectively (p less than 0.01 for both comparisons). The influenza group also had a higher proportion of patients with at least a 20% decrease in forced expiratory volume per second and forced expiratory flow in first 25% of vital capacity than the other two groups had (p less than 0.05 for all comparisons). These data suggest that influenza is associated with severe exacerbations in patients with cystic fibrosis and support recommendations for efforts to prevent influenza in this population.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2380817      PMCID: PMC7130847          DOI: 10.1016/s0022-3476(05)80530-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  Effects of acute viral respiratory tract infections in patients with cystic fibrosis.

Authors:  N L Hordvik; P König; B Hamory; M Cooperstock; C Kreutz; D Gayer; G Barbero
Journal:  Pediatr Pulmonol       Date:  1989

3.  What is a "pulmonary exacerbation" in cystic fibrosis?

Authors:  R E Wood; M W Leigh
Journal:  J Pediatr       Date:  1987-12       Impact factor: 4.406

4.  The chest roentgenogram in cystic fibrosis: a new scoring system.

Authors:  D Brasfield; G Hicks; S Soong; R E Tiller
Journal:  Pediatrics       Date:  1979-01       Impact factor: 7.124

Review 5.  Viral infection in cystic fibrosis.

Authors:  J Stroobant
Journal:  J R Soc Med       Date:  1986       Impact factor: 5.344

6.  Value of the C-reactive protein test in the differentiation of bacterial and viral pneumonia.

Authors:  P L McCarthy; A L Frank; R C Ablow; S J Masters; T F Dolan
Journal:  J Pediatr       Date:  1978-03       Impact factor: 4.406

7.  The effect of respiratory viral infections on patients with cystic fibrosis.

Authors:  B W Ramsey; E J Gore; A L Smith; M K Cooney; G J Redding; H Foy
Journal:  Am J Dis Child       Date:  1989-06

8.  The pediatrician's role in influenza control.

Authors:  W P Glezen
Journal:  Pediatr Infect Dis       Date:  1986 Nov-Dec

9.  Evaluation of the safety of amantadine-HC1 and the role of respiratory viral infections in children with cystic fibrosis.

Authors:  P F Wright; K T Khaw; M N Oxman; H Shwachman
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

10.  Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa.

Authors:  N T Petersen; N Høiby; C H Mordhorst; K Lind; E W Flensborg; B Bruun
Journal:  Acta Paediatr Scand       Date:  1981-09
View more
  27 in total

1.  Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Authors:  Edith T Zemanick; Brandie D Wagner; J Kirk Harris; Jeffery S Wagener; Frank J Accurso; Scott D Sagel
Journal:  Pediatr Pulmonol       Date:  2010-06

Review 2.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

3.  Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis.

Authors:  Mukta Jain; Anne H Thomson
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

4.  Optimization of influenza vaccine delivery to high risk children and adolescents.

Authors: 
Journal:  Paediatr Child Health       Date:  1999-11       Impact factor: 2.253

5.  Influenza vaccination in children at high risk of respiratory disease.

Authors:  Maria Francesca Patria; Claudia Tagliabue; Benedetta Longhi; Susanna Esposito
Journal:  Ther Adv Vaccines       Date:  2013-05

6.  Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.

Authors:  V Jullien; D Hubert; O Launay; G Babany; O Lortholary; I Sermet
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

Review 7.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Acute severe deterioration in cystic fibrosis associated with influenza A virus infection.

Authors:  S P Conway; E J Simmonds; J M Littlewood
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

9.  Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark.

Authors:  H K Johansen; N Høiby
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

10.  Influenza-associated cystic fibrosis pulmonary exacerbations.

Authors:  Justin R Ortiz; Kathleen M Neuzil; John C Victor; Anna Wald; Moira L Aitken; Christopher H Goss
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.